Press Release

Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty - Seite 2

Sanofi carries out more than 60% of its global production in the European Union and sources only 5% of its active ingredients in Asia, compared to an average of 80% in the pharmaceutical industry. Thanks to this industrial footprint, Sanofi's contribution to France's trade balance amounted to more than €13 billion in 2023.

These investments at Vitry, Le Trait and Lyon Gerland add up to major projects launched since the Covid-19 pandemic to build in France new drugs and vaccines production capacity in-line with Sanofi's world class pipeline of best and first-in-class assets and meet public health needs. These projects includes:

• In Neuville-sur-Saône, nearly €500 million to build the world's first evolutive facility for biological drugs and vaccines, including mRNA. It will be low-carbon and meet LEED certification standards when it launches in 2025.
• In Val de Reuil, €250 million to build Europe's largest flu vaccine production unit and locate several production stages of Fluzone High Dose / Efluelda, its high-dose flu vaccine, in France.
• In Sisteron, €60 million to build a small-volume launch unit for the production of active ingredients.
• In Lisieux, €20 million to increase Doliprane's production capacity by 140 million boxes per year.
• In Tours, €15 million to locate the production of a drug to fight high cholesterol in France. This investment will allow the construction of a new high-volume granulation unit and a tablet-coating line in a new building. The capacity of this new unit will be around 700 million boxes per year for some 20 countries, particularly in Europe and Asia.
  
  

Audrey Derveloy
President of Sanofi France
"Throughout its history, Sanofi has always sought to equip France with the strategic platforms needed to produce the essential medicines and vaccines of today and tomorrow. This is why we chose our Vitry site to double its monoclonal antibody production capacity, after having already invested heavily in Neuville-sur-Saône to produce our future vaccines, including with mRNA technology. We have also strengthened our API production sites in the south of France. Our contribution to health sovereignty in Europe, and France in particular, has always been and remains unique."